|
Basic clinical data, details of arthropathy, serologic findings, and therapy |
||||||||||
| Case |
Age/gender |
Clinical presentation and arthropathy |
Spleen, mm |
ANA |
RF IgM, IU/mL |
ANCA |
CCP |
aCL |
HP |
Therapy |
|
|
||||||||||
| 1 |
84/F |
RA (43 y), BCC (7 m), AITD, weight loss |
120 |
1/160 |
423 |
Neg |
Pos |
Pos |
Yes |
Corticosteroids |
| 2 |
56/F |
RA (10 y), BCC (6 y), amyloidosis AA |
115 |
1/160 |
320 |
Neg |
Pos |
ND |
Yes |
Corticosteroids |
| 3 |
75/F |
RA (7 y), BCC (2 y), weight loss |
180 |
1/160 |
125 |
Neg |
Pos |
ND |
Yes |
Corticosteroids |
| 4 |
36/F |
RA (18 y), BCC (4 y), AITD |
187 |
1/160 |
335 |
Neg |
Pos |
ND |
Yes |
Corticosteroids/MTX |
| 5 |
58/F |
RA (32 y), BCC (1 y), AITD |
95 |
1/160 |
97 |
Neg |
Pos |
ND |
Yes |
Corticosteroids/MTX |
| 6 |
74/M |
RA (10 y), BCC (3 y) |
150 |
1/320 |
325 |
Neg |
Pos |
Pos |
Yes |
Unknown |
| 7 |
57/M |
RA (10 y), BCC (3 y) |
200 |
1/160 |
320 |
ND |
Pos |
ND |
Yes |
Corticosteroids/MTX |
| 8 |
52/F |
UA (12 y), BCC (3 y), recurrent infections, skin lesions |
160 |
1/320 |
Neg |
Neg |
ND |
Pos |
Yes |
Corticosteroids |
| 9 |
68/F |
BCC (17 y), UA (2 y), recurrent infections, skin lesions |
185 |
1/80 dsDNA |
97 |
Neg |
Pos |
Pos |
Yes |
G-CSF/MTX |
| 10 |
51/F |
RA (8 y), rheumatoid nodules, BCC (3 y) |
185 |
1/160 |
450 |
Neg |
Pos |
Pos |
Yes |
MTX/CSA/Corticosteroids |
| 11 |
35/F |
RA (5 y), BCC (6 m) |
86 |
1/320 |
640 |
ND |
Pos |
ND |
Yes |
Corticosteroids |
| 12 |
50/F |
BCC (6 m) |
113 |
1/80 |
29 |
Pos/Neg |
Neg |
Pos |
Yes |
MTX |
| 13 |
28/F |
BCC (10 y), AITD |
103 |
Neg |
ND |
ND |
ND |
ND |
Yes |
None |
| 14 |
47/F |
BCC (1 y), AITD |
130 |
ND |
ND |
ND |
ND |
ND |
No |
Corticosteroids/MTX |
| 15 |
55/F |
BCC (1 y), glomerulonephritis (10 y) |
200 |
ND |
ND |
ND |
ND |
ND |
Yes |
MTX/Corticosteroids |
| 16 |
52/F |
BCC (2 y) |
115 |
Neg |
Neg |
Neg |
ND |
ND |
Yes |
CSA/G-CSF |
| 17 |
54/M |
BCC (3 y) |
145 |
Neg |
Neg |
Neg |
ND |
ND |
No |
Unknown |
| 18 |
70/M |
BCC (1 y), weight loss, skin lesions |
115 |
ND |
ND |
ND |
ND |
ND |
No |
MTX/Corticosteroids |
| 19 |
66/F |
BCC, recurrent infections, weight loss (10 y) |
120 |
Neg |
Neg |
ND |
ND |
ND |
Yes |
Unknown |
| 20 |
69/F |
BCC (6 y) |
125 |
Neg |
Neg |
ND |
ND |
ND |
Yes |
Unknown |
| 21 |
33/F |
BCC (6 m) |
150 |
1/80 |
160 |
ND |
ND |
ND |
Yes |
CSA |
|
aCL, anticardiolipin antibody; AITD, autoimmune thyroiditis; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; BCC, blood cell count abnormalities; CCP, anticyclic citrullinated peptide antibodies; CSA, cyclosporine A; dsDNA, double-stranded DNA; F, female; G-CSF, granulocyte-colony stimulating factor; HP, polyclonal hipergammaglobulinemia; m, months of observation; M, male; MTX, methotrexate; ND, not done; Neg, negative; Pos, positive; RA, rheumatoid arthritis; RF, rheumatoid factor; UA, unclassified arthritis; y, years of observation. | ||||||||||
Prochorec-Sobieszek et al. Arthritis Research & Therapy 2008 10:R55 doi:10.1186/ar2424 |
||||||||||